• en
  • fr

  • bioMérieux and its pledge to curb antibiotic resistance

    As world leader in microbiology, bioMérieux is dedicated to helping clinical labs provide actionable results faster, because time-to-diagnosis and therapeutic efficacy are paramount to infection control, preventing and managing multi-drug resistance and improving patient outcomes.

    Our high-medical value diagnostic tests enable timely detection and diagnosis of healthcare-associated and multi-drug resistant infections.

    bioMérieux provides clinical laboratories with a comprehensive range of diagnostic solutions for effective screening, infection control, outbreak management and appropriate antibiotic therapy guidance.

    OUR CLINICAL SOLUTIONS FOR ANTIBIOTIC RESISTANCE

    Infection Control

    Preventing and containing the spread of resistant bacteria in healthcare settings using screening tests, active surveillance, targeted isolation and environmental control systems is primordial to safeguard patients and help manage antibiotic resistance. bioMérieux’s offer covers a wide range of infection control solutions, including:

    The chromID™ range includes ready-to-use chromogenic culture media for the selective isolation, enumeration and identification of bacteria in 18-24 hours. Chromogenic media deliver more reliable differentiation of pathogens, faster and easier reading of results and enhanced sensitivity and specificity parameters than traditional culture media.

    RAPIDEC®-CARBA-NP

    RAPIDEC® CARBA NP is a rapid, high medical value test that confirms the presence of carbapenem resistance by detecting carbapenemase-producing bacteria from a culture. The test detects carbapenemase activity in the most frequently implicated Gram-negative bacteria such as Enterobacteriaceae, P. aeruginosa and A. baumannii in under 2 hours. The rapid detection time ensures appropriate therapy and isolation measures can be applied as quickly as possible, thereby improving patient management and controlling HAIs.

    Environmental_Control_Solutions

    Environmental Control Solutions include the diagnostic tools required for air, surface and water monitoring (including environmental, hemodialysis and endoscope disinfection control) and Legionella detection.

    Pathogen Identification

    Identification of the pathogen causing an infection is important to guide diagnosis and antibiotic therapy. bioMérieux covers the entire diagnostic spectrum of infectious diseases, from manual bacteriology tests to automated microbial identification/susceptibility systems to molecular diagnostics.

    FilmArray

    FilmArray® is a multiplex PCR system with a total run time of about one hour. The FilmArray® platform and its syndromic menu tests for a large variety of bacterial, fungal, viral and parasitic pathogens that cause respiratory, bloodstream, gastrointestinal and meningitis/encephalitis infections, as well as antibiotic resistance genes. Such rapid diagnostic tests that detect pathogens directly from clinical samples (e.g. stools for gastrointestinal infections or cerebrospinal fluid for meningitis/encephalitis infections) give the medical community highly valuable information, such as whether the infection is bacterial, fungal, parasitic or viral, helping to guide the prescription of antibiotics and avoid their misuse.

    Vitek_MS

    VITEK® MS is based on MALDI-ToF technology (matrix assisted laser desorption ionization time-of-flight mass spectrometry). VITEK® MS identifies the most common Gram-positive and Gram-negative bacteria and yeasts within minutes. This diagnosis is key to initiating timely and appropriate treatment.

    Vitek_2

    VITEK® 2 is an automated identification/susceptibility testing system capable of identifying the vast majority of routine organisms (over 300 microorganisms). Results can be obtained within hours thanks to the combination of analysis software and an original, miniaturized consumable, the VITEK® 2 card, which is available for a wide range of microorganisms.

     

    For more complex microorganisms, VITEK® 2 can be combined with complementary manual bacteriology methods: the API® range of products for pathogen identification, the Etest® for antibiotic susceptibility testing and the RAPIDEC® CARBA NP assay for targeted resistance detection (see below).

    API_ID

    The API® ID product range is a series of easy-to-use manual identification strips covering almost all groups of commonly occurring bacteria and yeasts isolated from clinical specimens. These standardized, miniaturized strips deliver reliable and accurate pathogen identification to confirm the causative agent and initiate appropriate treatment. The comprehensive apiweb internet database provides interpretive readings for each identification strip.

    Antibiotic susceptibility testing

    bioMérieux is recognized as the market leader in automated antimicrobial susceptibility testing (AST). As a pioneer in the field of resistance interpretation software, bioMérieux has integrated the Advanced Expert System (AES™), the reference in its field, into its flagship VITEK® 2 platform.

    Vitek_2

     The VITEK® 2 platform uses its in-built software solution, Advanced Expert System (AES™) to automatically compare every Minimum Inhibitory Concentration (MIC) result to an extensive knowledge base. The AES™ validates the results by expertly interpreting the antibiotic resistance profile of the identified bacteria.

    Etest
    Etest® is an agar-based antibiotic gradient method that provides antibiotic MIC values and tests a broad range of antimicrobial concentrations. It is the AST solution of choice to help determine the antibiotic concentration required to ensure therapeutic success in hard-to-treat cases: critically ill / immunocompromized patients, life-threatening infections (sepsis, pneumonia, endocarditis, meningitis), challenging organisms (P. aeruginosa, A. baumannii…) and bacteria associated with cystic fibrosis.

    Rapidec

    RAPIDEC® CARBA NP is a rapid, high medical value test that confirms the presence of carbapenem resistance by detecting carbapenemase-producing bacteria from a culture. The test detects carbapenemase activity in the most frequently implicated Gram-negative bacteria such as Enterobacteriaceae, P. aeruginosa and A. baumannii in under 2 hours. The rapid detection time ensures appropriate therapy and isolation measures can be applied as quickly as possible, thereby improving patient management and controlling HAIs.

    Outbreak management and surveillance

    Epidemiological surveillance tools are essential to track, contain and prevent the spread of pathogens at local, hospital, regional, national and international levels. Effective tracking of infectious agents and resistance patterns support the implementation of relevant infection control and antibiotic policies.

    EpiSeq

    The bioMérieux EpiSeq™ service is a NGS-based epidemiology tool developed for use by hospital epidemiologists and microbiologists to manage suspected HAI-related outbreaks as well as for epidemiological research. The service provides identification, typing, and comparative analysis of bacterial isolates for outbreak detection and epidemiological surveillance. For more information, see INNOVATION AND RESEARCH AND DEVELOPMENT

    Antibiotic prescription guidance

    Rationalizing antibiotic prescription to only treat when necessary is crucial in the fight against antibiotic resistance. bioMérieux provides rapid solutions that help determine whether the cause of the infection is bacterial or viral, thereby avoiding unnecessary prescription of antibiotics for viral infections.

    Vadis_BRAHMS

    VIDAS® B.R.A.H.M.S PCT™ is an automated test adapted for emergency conditions, which determines the level of procalcitonin (PCT) in human serum or plasma in just 20 minutes. PCT is a specific marker for the early detection of severe bacterial infections and sepsis. In February 2017, bioMérieux has received 510(k) clearance from the U.S. FDA (Food and Drug Administration) for the expanded use of VIDAS® B.R.A.H.M.S PCT™ to help clinicians make important decisions regarding the optimal use of antibiotics in two common clinical situations: lower respiratory tract infections (LRTI) and sepsis. Using VIDAS® B•R•A•H•M•S PCT™ in these frequent and important clinical situations will help reduce inappropriate and unnecessary antibiotic use, which may avoid the side effects associated with their use while slowing and preventing the emergence of resistant bacteria.

    Rapid tests are valuable allies to reduce antibiotic use. Used in hospital or primary care settings, these non-invasive tests provide fast answers for common infections:

    • bioNexia® Strep A panel enables identification of a bacterial “Strep A” throat infection in 5 minutes, making these rapid tests a cost-effective solution for patient management. Rapid diagnosis helps physicians reduce the risk of severe post-streptococcal complications, minimize the spread of infection and prescribe antibiotics only when necessary.
    • bioNexia® Influenza A+B is a rapid test able to detect influenza A viruses (including H1N1, H5N1, H3N2) and differentiate influenza A and influenza B viruses in 10 minutes. Rapid, accurate diagnosis means reducing the risk of transmission and outbreak, preventing inappropriate antibiotic use and ensuring early prescription of antiviral medication.